Hemoglobin-based blood substitutes and risk of myocardial infarction and death

JAMA

Volumn 300, Issue 11, 2008, Pages 1297-

  Sauaia, Angela ^a   Moore, Ernest E ^a   Banerjee, Anirban ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL BLOOD; BLOOD SUBSTITUTE;

BLOOD BANK; BLOOD DONOR; BLOOD STORAGE; BLOOD TRANSFUSION; INFECTION; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 51949118416     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.11.1297-a     Document Type: Letter

References (5)

1. Fergusson DA, McIntyre L. The future of clinical trials evaluating blood substitutes. JAMA. 2008;299(19):2324-2326.
2. ABC blood supply status report as of August 6, 2008. America's Blood Centers Web site. http://www.americasblood.org. Accessed August 6, 2008.
3. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA. 2003;289(8):959-962.
4. Moore EE, Cheng A, Moore H, Masuno T, Johnson J. Hemoglobin-based oxygen carriers in trauma care: scientific rationale for the US multicenter prehospital trial. World J Surg. 2006;30(7):1247-1257.
5. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobinbased blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299(19):2304-2312.